The National Cancer Institute (NCI) is seeking grant applications for the development of innovative technologies to improve the quality and handling of cancer research biospecimens. This includes tools to address issues related to pre-analytical degradation during the collection, processing, handling, and storage of cancer-relevant samples. The overall goal is to support the creation of highly innovative technologies that can maximize the quality and utility of biological samples used for downstream cancer research and clinical analyses. Eligible applicants include higher education institutions, government entities, nonprofits, and small businesses. The grant opportunity, RFA-CA-25-003, is part of NCI's Innovative Molecular Analysis Technologies (IMAT) Program and falls under the Cancer Detection and Diagnosis Research funding mechanism (CFDA 93.394).
This funding opportunity does not specify a fixed award amount, but past projects under the Cancer Detection and Diagnosis Research program have received between $200,000 to over $1.6 million in total costs, with typical project periods spanning 2-5 years. The research is expected to be conducted at the applicant's facilities across the United States, with some international collaboration components possible, particularly for clinical trials networks.
Generated 12/18/24, 6:13 AM